This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of ACP on Surgical Repair of Rotator Cuff Tears

This study has been completed.
Sponsor:
Collaborator:
Arthrex, Inc.
Information provided by (Responsible Party):
Matthias Flury, Schulthess Klinik
ClinicalTrials.gov Identifier:
NCT01266226
First received: December 22, 2010
Last updated: May 19, 2015
Last verified: May 2015
History of Changes
  Purpose
The purpose of this study is to determine if autologous plasma (ACP) is beneficial for better and faster healing following an arthroscopic repair of the rotator cuff.

Condition Intervention
Rotator Cuff Tears Device: Autologous conditioned plasma Device: Control group

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Autologous Plasma (ACP) on Surgical Repair of Rotator Cuff Tears

Resource links provided by NLM:

MedlinePlus related topics: Tears
U.S. FDA Resources

Further study details as provided by Matthias Flury, Schulthess Klinik:

Primary Outcome Measures:
  • Oxford Shoulder Score [ Time Frame: 3mo (6mo/24mo) ]
    The Oxford Shoulder Score used after 3 months is the primary parameter. The Score tests the ability to participate in the patients' normal life before they got injured.


Secondary Outcome Measures:
  • VAS Pain [ Time Frame: 10d po ]
  • QuickDASH [ Time Frame: 3/6/24mo ]
  • EQ-5D [ Time Frame: 3/6/24 mo ]
  • ROM [ Time Frame: 3/6/24mo ]
  • Measurement of the abduction strength [ Time Frame: 3/6/24 mo ]
  • ASES Score [ Time Frame: 3/6/24mo ]
  • Constant Murley Score [ Time Frame: 3/6/24 mo ]
  • MRI/X-Ray/Ultrasonic Diagnostics [ Time Frame: 6/24 mo ]
  • Measurement of the external rotation strenght [ Time Frame: 3/6/24 mo ]
Enrollment: 129
Study Start Date: December 2010
Study Completion Date: February 2015
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ACP treated
The patients are going to get an injection of 4mL autologous conditioned plasma under the footprint following an arthroscopic repair of the rotator cuff.
 Device: Autologous conditioned plasma
4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
Other Name: ACP Arthrex
Placebo Comparator: Control group
The patients are going to get an injection of 4mL saline solution under the footprint following an arthroscopic repair of the rotator cuff.
 Device: Control group
4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
Other Name: ACP Arthrex

Detailed Description:

The shoulder joint, specially the rotator cuff, is one of the most complicated joints of the human body. If the tendon has to be fixed at the bone during surgery, the weak point in obtaining a successful surgery is the fixation of the tendon at the bone insertion site. Tendon belongs to the bradytrophic tissue conditional on the reduced blood flow, deep mitosis rate and lowered healing potential. We can boost the healing process with a selective use of PRP (platelet rich plasma). In this process, the healing site is delivered with an elevated concentration of thrombocytes and also growth factors which are constituent parts of them.

In this study, we will test the Arthrex® Double Syringe System. With this system it is possible to obtain ACP (Autologous conditioned plasma) in one centrifugation step. The supernatant contains a concentration of thrombocytes which is twice as high as in the native blood. The concentration of the growth factors is 5-25x higher according to this.

We also want to test if one application of ACP is enough to get a short- and long-term benefit in healing following a rotator cuff tear.

  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Arthroscopic rotator cuff reconstructions of degenerative or traumatic full thickness rotator cuff tears (supraspinatus and/or infraspinatus tendon) performed by Dr. Flury and Dr. Schwyzer
  • Suture bridge technique
  • No pregnancy at the date of the surgery for women of childbearing potential
  • Signed consent form

Exclusion Criteria:

  • Partial reconstruction of the rotator cuff (PASTA)
  • Open reconstruction
  • Tendon transfer (latissimus dorsi or pectoralis major)
  • Revision surgery
  • Omarthrosis (Level ≥ 2 Samilson & Prieto)
  • Systemic arthritis
  • Rheumatoid arthritis
  • Diabetes (insulin treated)
  • Requiring surgery in reconstruction of the subscapularis tendon
  • Progressive fat inclusion (fatty infiltration of the rotator cuff musculature Goutallier level IV
  • Acute or chronic infection
  • Pathological bone metabolism
  • Insufficient perfusion in the affected arm
  • Neuromuscular disease in the affected arm
  • Non compliance of the patient
  • Disorders which handicap or inhibit the patient to follow the orders of the clinical testers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01266226

Locations
Switzerland
Schulthess Klinik
Zürich, Canton Zürich, Switzerland, 8008
Sponsors and Collaborators
Schulthess Klinik
Arthrex, Inc.
Investigators
Principal Investigator: Matthias Flury, Dr Upper Extremities Department
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Matthias Flury, Principal Investigator, Schulthess Klinik
ClinicalTrials.gov Identifier: NCT01266226     History of Changes
Other Study ID Numbers: ACP01
KEK-ZH-Nr. 2010-0309/4 ( Other Identifier: Regional Ethics Committee of Zurich )
Study First Received: December 22, 2010
Last Updated: May 19, 2015

Keywords provided by Matthias Flury, Schulthess Klinik:
Rotator cuff tears
ACP

ClinicalTrials.gov processed this record on August 16, 2017